Washington, DC — After years of runaway spending, the Centers for Medicare & Medicaid Services (CMS) is moving to cut payments for high-priced wound care products known as “skin substitutes” by 90% starting in January 2026. The agency’s decision follows an explosive surge in Medicare spending on these products—from $256 million in 2019 to more than $10 billion in 2024.
A 3,800% Spending Surge Raises Red Flags
According to CMS, the reclassification of skin substitutes from “biologicals” to “incident-to supplies” is expected to save the government nearly $19.6 billion in 2026 alone. The shift comes after years of apparent oversight failures that allowed a niche category of wound care products to balloon into a multibillion-dollar drain on the Medicare budget.
Industry observers say the spike in spending went largely unnoticed by federal watchdogs, even though Medicare maintains sophisticated billing systems, fraud detection programs, and auditing teams designed to flag anomalies. “It’s stunning this kind of growth didn’t raise alarms sooner,” one healthcare policy analyst said.
From Luxury Labels to Basic Supplies
The reclassification means that skin substitutes—once treated as advanced biological materials with premium reimbursement—will now be billed like standard medical supplies. Under the old system, CMS essentially reimbursed providers at high rates for products marketed as complex “biologicals.” By treating them as routine supplies, the agency will dramatically reduce reimbursement levels.
To put the cost in perspective, some of these wound care sheets were billed at prices exceeding $2,000 per square centimeter—more expensive than gold by weight.
Fraud Case Highlights Oversight Failures
The scale of questionable billing came into sharp focus in late 2025 when CMS’s Fraud Defense Operations Center halted $4.3 million in suspected improper payments tied to a single medical group. Nearly all the claims were for wound care provided to one beneficiary who lacked any documented history of wounds.
The case raised serious questions about how such excessive claims could slip through multiple layers of Medicare oversight for years. In 2025 alone, CMS reported identifying $185 million in improper payments related to wound care, suggesting that many similar cases may have gone undetected before that.
SNFs and the Perverse Incentive Problem
The policy shift also holds implications for skilled nursing facilities (SNFs), where pressure ulcers are a common challenge. Under the prior reimbursement model, there was an unintended incentive for larger, poorly healing wounds to generate more revenue due to the expanding surface area eligible for high-cost products.
While most SNFs adhere to clinical best practices, the system’s design meant that effective wound management could paradoxically result in lower billing potential. The new payment structure is intended to remove those distortions and align reimbursement with appropriate care costs.
The Bigger Question: What Else Is Hiding in the Budget?
The revelation has prompted broader concerns about Medicare’s financial oversight. If $10 billion could flow to a single product category with “limited clinical evidence,” critics ask, how many other spending outliers remain buried within the program’s nearly $1 trillion budget?
Looking Ahead
CMS expects the new rules to take effect at the start of 2026, ending what officials now acknowledge was years of unchecked growth. Some wound care providers and suppliers may close or consolidate as a result, reshaping a corner of the healthcare market that quietly became one of Medicare’s most expensive line items.
